Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belzutifan - Merck & Co

Next Previous
Drug Profile

Belzutifan - Merck & Co

Alternative Names: MK 6482; PT-2977; WELIREG; WELIREGTM

Latest Information Update: 26 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peloton Therapeutics
  • Developer Eisai Inc; Merck & Co; Merck Sharp & Dohme; Peloton Therapeutics
  • Class Antineoplastics; Benzonitrile; Fluorobenzenes; Indenes; Small molecules; Sulfones
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Hippel-Lindau disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Paraganglioma; Phaeochromocytoma; Renal cell carcinoma; Von Hippel-Lindau disease
  • Preregistration Neuroendocrine tumours
  • Phase II Gastrointestinal stromal tumours; HER2 negative breast cancer; Solid tumours
  • Phase I/II Prostate cancer
  • Discontinued Iron overload

Most Recent Events

  • 26 Aug 2025 Merck Sharp & Dohme initiates phase-I/II clinical trials in Renal cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel and USA (PO) (NCT07049926)
  • 18 Aug 2025 Merck Sharp & Dohme LLC plans a phase I trial (In volunteers) in August 2025 (PO, Tablet) (NCT07121959)
  • 03 Jul 2025 Merck Sharp & Dohme plans a phase I/II trial in Renal cell carcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) (PO) in August 2025 (NCT07049926)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top